Trevena Appoints Barry Shin as Chief Financial Officer
June 27, 2019 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., June 27, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Publication of APOLLO-2 Results in Pain Practice
June 24, 2019 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., June 24, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Initiation of Healthy Volunteer Study for Oliceridine
June 20, 2019 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., June 20, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) (“Trevena” or the “Company”), a biopharmaceutical company focused on the development and commercialization of novel...
Trevena Reports First Quarter 2019 Results
May 10, 2019 07:00 ET
|
Trevena Inc.
— Company announces receipt of FDA feedback on healthy volunteer study protocol and analysis plan for oliceridine — – Study on track to initiate by end of June – Company to host conference call...
Trevena Reports Fourth Quarter and Full Year 2018 Results
March 13, 2019 07:00 ET
|
Trevena Inc.
— Company announces submission of oliceridine healthy volunteer study protocol and analysis plan to FDA — — Successful fundraising extends cash runway into 3Q 2020 —Company to host conference call...
Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain
March 11, 2019 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., March 11, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of innovative treatment options that...
Trevena to Present at the 21st Annual BIO CEO & Investor Conference
February 05, 2019 18:58 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment options...
Trevena Announces $10 Million Registered Direct Offering of Common Stock
January 30, 2019 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Jan. 30, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) (the “Company”) today announced that it entered into securities purchase agreements with two healthcare-focused...
Trevena Announces Receipt of Type A Meeting Minutes and Provides Regulatory Update for Oliceridine
January 28, 2019 07:00 ET
|
Trevena Inc.
– Company announces initial path forward on oliceridine NDA – – Company to host conference call on Monday, January 28 at 8:30 a.m. ET – CHESTERBROOK, Pa., Jan. 28, 2019 (GLOBE NEWSWIRE) --...
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Trevena, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
December 10, 2018 11:30 ET
|
Schall Law
LOS ANGELES, Dec. 10, 2018 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Trevena, Inc. (“Trevena” or...